Takeda Pharma USA Inc v. Polpharma Biologics SA

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Takeda Pharmaceuticals U.S.A., Inc. (Delaware) and Takeda Pharmaceuticals International AG (Switzerland)
  • Defendant: Polpharma Biologics S.A. (Poland)
  • Plaintiff's Counsel: Morgan, Lewis & Bockius LLP
• Case Identification: 3:26-cv-11002, D.N.J., 08/26/2026
• Venue Allegations: Venue is alleged to be proper because the defendant, Polpharma, is a foreign entity and therefore subject to suit in any U.S. judicial district. Plaintiffs further allege that Polpharma has transacted business in New Jersey and will commit acts of patent infringement in the district.
• Core Dispute: Plaintiff alleges that Defendant's proposed biosimilar vedolizumab product, PB016, will infringe six U.S. patents covering the approved biologic drug ENTYVIO® and its methods of use for treating inflammatory bowel disease.
• Technical Context: The technology is in the field of biologic therapeutics, specifically a humanized monoclonal antibody that selectively targets the α4β7 integrin pathway to treat inflammatory bowel disease (IBD), a market with multi-billion dollar annual sales.
• Key Procedural History: This action was filed under the Biologics Price Competition and Innovation Act (BPCIA) following Defendant's submission of an abbreviated Biologics License Application (aBLA) for a biosimilar version of Plaintiff's drug, ENTYVIO®. The complaint states that Defendant provided a Notice of Commercial Marketing on June 18, 2026, and declined to participate in the "patent dance" information exchanges established by the BPCIA.

Case Timeline

Date	Event
2011-05-02	Earliest Priority Date for '808, '526, '832, '445, '969 Patents
2014-05-01	FDA approves ENTYVIO® for intravenous administration
2017-05-30	'579 Patent Issued
2018-06-26	'808 Patent Issued
2021-01-01	Polpharma's efforts to copy ENTYVIO® allegedly began "as early as 2021"
2023-07-24	Polpharma initiates Phase III clinical trial for PB016
2024-02-01	Polpharma announces pharmacokinetic comparability of PB016 to ENTYVIO®
2024-04-01	FDA approves ENTYVIO® for subcutaneous delivery
2024-08-06	'526 Patent Issued
2024-12-24	'832 Patent Issued
2025-01-01	Polpharma announces partnership with Fresenius Kabi
2026-02-10	'445 Patent Issued
2026-05-12	'969 Patent Issued
2026-06-18	Polpharma provides Takeda with Notice of Commercial Marketing for its aBLA Product
2026-08-26	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,663,579 - "Formulation for anti-a4β7 Antibody," Issued May 30, 2017

The Invention Explained

• Problem Addressed: The complaint alleges that earlier biologic therapies for inflammatory bowel disease (IBD) were associated with significant toxicities from chronic systemic immunosuppression Compl. ¶5 Additionally, early formulations of vedolizumab, the active ingredient in ENTYVIO®, produced high rates of anti-drug antibodies, which could reduce the drug's efficacy Compl. ¶26
• The Patented Solution: The '579 Patent claims a specific method of treatment for Crohn's disease (CD) in a defined patient population: those who have failed or are intolerant to TNFα antagonist therapies Compl. ¶54 The solution involves administering a 300 mg dose of a specific anti-α4β7 antibody at an induction schedule of week 0, week 2, and week 6 to achieve a clinical response Compl. ¶54 This dosing regimen was developed to reduce the immunogenicity observed in earlier studies Compl. ¶26
• Technical Importance: This dosing method provided an effective treatment for a difficult-to-treat patient population while minimizing the development of anti-drug antibodies, which was a significant hurdle for biologic therapies Compl. ¶¶26-27

Key Claims at a Glance

• The complaint asserts infringement of at least claim 1 (Compl. ¶56).
• Independent claim 1 of the '579 Patent includes the following essential elements:
  • A method for achieving clinical response of Crohn's disease in a human patient.
  • The method comprises intravenously administering an antibody to a patient who had a lack of an adequate response with, lost response to, or was intolerant to a TNFα antagonist.
  • The antibody has binding specificity for human α4β7 integrin.
  • The administration schedule is a first dose of 300 mg, a second dose of 300 mg two weeks later, and a third dose of 300 mg six weeks after the first dose.
  • The antibody comprises specific heavy and light chain variable region amino acid sequences (SEQ ID NO:2 and SEQ ID NO:4).

U.S. Patent No. 10,004,808 - "Methods of Treating Ulcerative Colitis," Issued June 26, 2018

The Invention Explained

• Problem Addressed: The patent's background describes the need for stable, convenient, and effective treatments for inflammatory bowel disease, noting that previous antibody formulations were susceptible to degradation and instability '808 Patent, col. 1:21-54 The complaint highlights that prior therapies often involved broad immunosuppression with significant side effects Compl. ¶4
• The Patented Solution: The '808 Patent claims a method for inducing clinical remission of ulcerative colitis (UC) by administering a specific anti-α4β7 antibody (vedolizumab) according to a multi-phase dosing regimen '808 Patent, abstract This regimen comprises an induction phase (300 mg doses at weeks 0, 2, and 6) followed by a maintenance phase (300 mg every eight weeks) '808 Patent, claim 1 This approach provides a gut-selective mechanism that avoids systemic immunosuppressive effects while maintaining long-term efficacy Compl. ¶4
• Technical Importance: The invention provided the first approved gut-selective biologic for IBD, offering an improved safety profile over existing treatments that carried risks of serious systemic side effects '808 Patent, col. 8:19-31 Compl. ¶30

Key Claims at a Glance

• The complaint asserts infringement of at least claim 1 Compl. ¶80
• Independent claim 1 of the '808 Patent includes the following essential elements:
  • A method for inducing clinical remission in a human patient with moderately to severely active ulcerative colitis.
  • The method comprises intravenously administering an antibody that binds to human α4β7 integrin.
  • The administration schedule is a first dose of 300 mg, a second dose of 300 mg two weeks later, a third dose of 300 mg six weeks after the first dose, and then 300 mg every eight weeks thereafter.
  • The antibody comprises specific heavy and light chain variable region amino acid sequences (SEQ ID NO:2 and SEQ ID NO:4).
  • The patient had a lack of an adequate response with, lost response to, or was intolerant to a TNFα antagonist.

Multi-Patent Capsule: U.S. Patent No. 12,053,526 - "Methods for Treatment Using anti-alpha4beta7 Antibody," Issued August 6, 2024

• Technology Synopsis: This patent is directed to methods for treating UC by administering a humanized immunoglobulin (vedolizumab) according to a specific dosing regimen to induce clinical response and remission Compl. ¶102 The claimed method also results in the patient having a low titer of human anti-human antibodies (HAHA), addressing the problem of immunogenicity (Compl. ¶¶26; Compl. ¶102, claim 7).
• Asserted Claims: Representative claim 7 (independent) is recited in the complaint Compl. ¶102
• Accused Features: The complaint alleges that Defendant's aBLA Product, PB016, will be administered according to the claimed dosing regimen to treat UC, inducing clinical remission and tolerance (a low HAHA titer) in patients Compl. ¶¶103-105 Compl. ¶¶109-110

Multi-Patent Capsule: U.S. Patent No. 12,171,832 - "Methods of Treating Ulcerative Colitis," Issued December 24, 2024

• Technology Synopsis: This patent claims methods for treating UC in patients who have had an inadequate response to prior immunomodulator therapies (azathioprine or 6-mercaptopurine) Compl. ¶128 The method involves a specific intravenous dosing regimen of a humanized antibody (vedolizumab) defined by its CDR sequences, and specifies clinical response and remission milestones at 6 weeks and 52 weeks, respectively Compl. ¶128, claim 1
• Asserted Claims: Representative claim 1 (independent) is recited in the complaint Compl. ¶128
• Accused Features: The complaint alleges that the labeling for Defendant's aBLA Product will encourage its use in the specified patient population according to the claimed dosing regimen, achieving the claimed clinical outcomes Compl. ¶¶129-131 Compl. ¶133

Multi-Patent Capsule: U.S. Patent No. 12,544,445 - "Methods for Treatment Using anti-α4β7 Antibody," Issued February 10, 2026

• Technology Synopsis: This patent is directed to methods of treating IBD (CD or UC) using a specific two-phase (induction and maintenance) dosing regimen of a humanized antibody (vedolizumab) Compl. ¶153 The claim requires that the method induces clinical response and remission and achieves a specific mean trough serum concentration of the antibody at the end of the induction phase Compl. ¶153, claim 1
• Asserted Claims: Representative claim 1 (independent) is recited in the complaint Compl. ¶153
• Accused Features: The complaint alleges that administering Defendant's aBLA Product according to its recommended dosing will produce the claimed trough serum concentration and induce the claimed clinical outcomes in IBD patients (Compl. ¶154; Compl. ¶155; Compl. ¶156; Compl. ¶157; Compl. ¶158).

Multi-Patent Capsule: U.S. Patent No. 12,622,969 - "Methods for Treatment Using anti-α4β7 Antibody," Issued May 12, 2026

• Technology Synopsis: This patent claims methods for treating IBD (CD or UC) and for minimizing the formation of human antihuman antibodies (HAHA) Compl. ¶178 The method involves a specific two-phase dosing regimen and requires that at least 80% of patients are maintained as HAHA-negative for at least 6 weeks Compl. ¶178, claim 1
• Asserted Claims: Representative claim 1 (independent) is recited in the complaint Compl. ¶178
• Accused Features: The complaint alleges that administering Defendant's aBLA Product according to its recommended dosing will result in at least 80% of patients being HAHA-negative for the required duration, thereby infringing the claim (Compl. ¶¶179; Compl. ¶183).

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Defendant Polpharma's aBLA Product, identified as PB016, which is a proposed biosimilar version of Plaintiff's ENTYVIO® biologic drug Compl. ¶7

Functionality and Market Context

The aBLA Product is described as a biosimilar vedolizumab product for intravenous infusion Compl. ¶7 Vedolizumab is a humanized IgG1 monoclonal antibody that binds to the human α4β7 integrin to treat moderately to severely active UC and CD Compl. ¶1 Compl. ¶36 The complaint alleges the aBLA Product is designed to be "highly similar" to ENTYVIO® so that it can be substituted in the market Compl. ¶8 A screenshot from an exhibit shows the recommended intravenous dosage for ENTYVIO®, which the complaint alleges the aBLA Product will adopt Compl. p. 9, citing Ex. 7 at § 2.2 Polpharma is alleged to be targeting a market with over $5.3 billion in annual sales Compl. ¶34

IV. Analysis of Infringement Allegations

U.S. Patent No. 9,663,579 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method for achieving clinical response of Crohn's disease in a human patient, comprising intravenously administering to a human patient with Crohn's disease, wherein said human patient had a lack of an adequate response with, lost response to, or was intolerant to a TNFα antagonist:	Polpharma's aBLA Product will be labeled for the treatment of moderately to severely active CD, and its label will allegedly encourage use in patients who have failed TNFα antagonist therapy.	¶55; ¶60	The complaint does not cite the patent specification for this element.
a first dose of 300 mg of an antibody that has binding specificity for human α4β7 integrin, a second dose of 300 mg of the antibody two weeks after the first dose, and a third dose of 300 mg of the antibody six weeks after the first dose,	The aBLA Product will be administered according to this specific induction dosing regimen, as promoted by its label.	¶57	The complaint does not cite the patent specification for this element.
wherein the antibody comprises the heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO:2, and the light chain variable region sequence of amino acids 20 to 131 of SEQ ID NO:4.	The active ingredient in the aBLA Product is vedolizumab, which is an antibody comprising these specific amino acid sequences.	¶59	The complaint does not cite the patent specification for this element.

U.S. Patent No. 10,004,808 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method for inducing clinical remission in a human patient having moderately to severely active ulcerative colitis, comprising intravenously administering:	Polpharma seeks approval for its aBLA Product for the treatment of moderately to severely active UC and will encourage its use for this indication via its label.	¶79	col. 1:1-3
a first dose of 300 mg of an antibody that has binding specificity for human α4β7 integrin, a second dose of 300 mg of the antibody two weeks after the first dose, a third dose of 300 mg of the antibody six weeks after the first dose, and then 300 mg of the antibody every eight weeks thereafter,	The aBLA Product will be administered according to this induction and maintenance dosing regimen, as encouraged by its label.	¶81	col. 5:8-21
wherein the antibody comprises the heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO:2, and the light chain variable region sequence of amino acids 20 to 131 of SEQ ID NO:4,	The active ingredient in the aBLA Product is vedolizumab, which is an antibody comprising these specific amino acid sequences.	¶83	col. 5:67-6:11
and wherein said human patient had a lack of an adequate response with, lost response to, or was intolerant to a TNFα antagonist.	Polpharma's label will allegedly promote use in UC patients who have failed TNFα antagonist therapy, and Polpharma's clinical trials specifically targeted this patient population.	¶84	col. 29:64-30:24

Identified Points of Contention

• Scope Questions: The asserted claims are directed to methods of treatment that require specific outcomes (e.g., "achieving clinical response," "inducing clinical remission"). A central question for the court will be whether the administration of Defendant's aBLA Product, as instructed by its eventual FDA-approved label, will in fact result in these claimed outcomes in the specified patient populations.
• Technical Questions: A key evidentiary question will be how closely the patient populations targeted by the aBLA Product's label and marketing materials align with the specific populations recited in the claims (e.g., patients who have failed or are intolerant to TNFα antagonists). The complaint suggests this will be a direct overlap, citing Polpharma's own clinical trial design which allegedly targeted these exact patient groups Compl. ¶60 Compl. ¶84

V. Key Claim Terms for Construction

The Term: "a lack of an adequate response with, lost response to, or was intolerant to a TNFα antagonist" (from claim 1 of the '579 and '808 patents)

• Context and Importance: This phrase defines the specific patient population for the claimed methods. The construction of this term is critical because infringement can only occur if the accused product is used to treat patients who fall within this definition. Practitioners may focus on this term because it limits the scope of the claims to a subset of all IBD patients, and the evidence of infringement will depend on showing that Polpharma's product is intended for this specific subset.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The complaint does not provide specific patent language that would support a broad interpretation, but a party could argue that the plain and ordinary meaning should apply, encompassing any clinically recognized failure of TNFα antagonist therapy.
  • Evidence for a Narrower Interpretation: The specification of the '808 Patent provides explicit definitions for what constitutes an "inadequate response to a TNF-α antagonist," including specific examples such as failure to respond to an induction regimen of infliximab, adalimumab, or certolizumab pegol '808 Patent, col. 30:2-24 A party could argue these specific examples limit the scope of the term to only those scenarios described.

The Term: "inducing clinical remission" (from claim 1 of the '808 patent)

• Context and Importance: This term defines the required therapeutic outcome of the claimed method. Its construction will be central to determining whether the use of the accused product meets this claim limitation. Practitioners may focus on this term because proving that an accused method achieves a specific clinical outcome is a key element of infringement.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: A party could argue for a general clinical understanding of "remission" based on the ordinary meaning to a person of skill in the art at the time of the invention.
  • Evidence for a Narrower Interpretation: The specification of the '808 Patent defines "clinical remission" for ulcerative colitis with high specificity as "a complete Mayo score of 2 or less points and no individual subscore greater than 1 point" '808 Patent, col. 13:67-14:2 A party would likely argue that this explicit definition provides the controlling, and therefore narrower, meaning of the term.

VI. Other Allegations

Indirect Infringement

The complaint alleges that Polpharma will induce infringement by encouraging, promoting, and recommending that healthcare providers and patients use the aBLA Product in an infringing manner Compl. ¶¶63, 87 This encouragement is alleged to be provided through the product's label and prescribing information, which will allegedly instruct the performance of the patented methods Compl. ¶¶55, 79

Willful Infringement

The complaint alleges that Polpharma is "aware, knows, and/or is willfully blind" to the fact that its actions will infringe the asserted patents Compl. ¶¶62, 86 The basis for this knowledge is alleged to include the filing of the complaint itself, as well as an assertion, on information and belief, that Polpharma was aware of the patents prior to the lawsuit being filed Compl. ¶¶64, 88

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of inducement and intent: assuming Polpharma's biosimilar product is approved, will its final FDA-approved label and associated marketing materials contain instructions or recommendations that are specific enough to encourage medical professionals to perform the exact steps of the patented methods, thereby establishing the specific intent required for induced infringement?
• A second key question will be one of claim scope and evidence: how will the court define the clinical outcome limitations, such as "inducing clinical remission," and what level of evidence from Polpharma's aBLA and clinical trial data will be necessary to prove that the use of the accused product will meet these required outcomes in the specified patient populations?
• A final central question will be one of definitional overlap: can Takeda demonstrate that the patient population defined in its claims (e.g., those who have failed TNFα antagonist therapy) is the same population for which Polpharma will actively promote its biosimilar product, and does the evidence from Polpharma's own clinical trials and regulatory submissions support this alignment?